Physician profile
Sualeh Ashraf
NPI 1457306342
$829.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.69 · 2022: $187 · 2023: $590 · 2024: $35.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $190.27 | 2023 | Amplatzer Amulet, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $112.89 | 2023 | Farxiga, Brilinta |
| Amgen INC. | $105.52 | 2023 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.43 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $59.24 | 2021-2023 | Verquvo, Steglatro |
| Medtronic, INC. | $48.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $39.83 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $35.96 | 2023-2024 | |
| Lilly USA, LLC | $35.59 | 2022-2023 | Mounjaro, Humulin |
| Insulet Corporation | $35.53 | 2022-2023 | Omnipod |
| Novo Nordisk INC | $23.71 | 2022 | |
| Tandem Diabetes Care, INC. | $22.15 | 2022 | |
| Corcept Therapeutics | $21.29 | 2023 | Korlym |
| Ascensia Diabetes Care US INC. | $19.32 | 2023 | |
| Xeris Pharmaceuticals, INC. | $15.96 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sualeh Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.